Abstract: A serum resistin level reducing agent that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level, as an agent for oral administration. A food or beverage composition for reducing a serum resistin level that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level. A method of reducing a serum resistin level by applying a cell wall disrupted product of a chlorella for oral administration. A use of a cell wall disrupted product of a chlorella for oral administration for reducing a serum resistin level.

Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.

Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.

Abstract: A serum resistin level reducing agent that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level, as an agent for oral administration. A food or beverage composition for reducing a serum resistin level that comprises a cell wall disrupted product of a Chlorella pyrenoidos, and that reduces a serum resistin level. A method of reducing a serum resistin level by applying a cell wall disrupted product of a chlorella for oral administration. A use of a cell wall disrupted product of a chlorella for oral administration for reducing a serum resistin level.

Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.

Abstract: Provided is a pharmaceutical composition for reducing the risk in a patient at high risk for occurrence and/or recurrence of a cardiovascular event by administering the composition to the patient with a high ratio of oleic acid to stearic acid in plasma. The pharmaceutical composition contains ethyl icosapentate as its effective component. The composition is expected to reduce the risk in the patient at high risk for occurrence and/or recurrence of a cardiovascular event, and particularly to have a preventive effect on occurrence and/or recurrence of a cardiovascular event in the patient with a high ratio of oleic acid to stearic acid in plasma.

Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.

Abstract: A method for measuring antioxidant activity of test samples, which attains higher sensitivity than the conventional methods is disclosed. In the method of this invention, methemoglobin, an oxidizing agent which oxidizes methemoglobin, a coloring agent which generates color by reaction with methemoglobin in the presence of the oxidizing agent, and a test sample whose antioxidant activity is to be measured are reacted, and the generated color is measured.

Abstract: Described are a lipoprotein (a) lowering agent and a cholesterol lowering agent each comprising as an effective ingredient a proanthocyanidin contained in a grape extract or the like; and medicaments comprising the lowering agents, respectively.